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per patient was R$27,359 (€9,877) for octreotide LAR and
R$46,287 (€$16,710) for lanreotide SR. Net savings per
patient per year with octreotide LAR were R$18,928 (€6,833).
Sensitivity analysis did not revert results of net savings.
CONCLUSIONS: Monitoring of acromegaly treatment costs
after reimbursement for somatostatin analogues showed that
octreotide LAR is cost-saving compared to lanreotide SR in
Brazil under the Public Health Care System perspective.
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OBJECTIVES: The objective of this study was to estimate cost-
utility of biphasic insulin aspart (BIAsp) versus biphasic human
insulin (BHI) in type 2 diabetes patient’s diagnosed and treated in
tier III urban hospitals in China. METHODS: A published, vali-
dated, peer-reviewed computer simulation model of diabetes (the
CORE Diabetes Model) was used to project short-term results
obtained from a large, 26-week, observational study conducted
across China. 474 Chinese patients were switched from BHI to
BIAsp and results were entered into the model. Complication
cost data and a survey of treatment management practices were
collected from secondary care centres independent of the obser-
vational study, to avoid protocol costs. Market prices of drugs
and glucose monitoring tests were used. Patient baseline charac-
teristics included the mean age (57.9 years), duration of diabetes
(7.98 years) and baseline HbA1c (8.55%). Life expectancy,
quality adjusted life expectancy and total direct medical costs
(complications + treatment costs) were projected over patient
lifetimes (30 years), and were discounted at 3% per annum in
line with local pharmacoeconomic guidelines. RESULTS:
Improved glycemic control and lower hypoglycemic event rates
associated with BIAsp therapy led to an increase in life expect-
ancy (mean  sd) of 0.261 years (10.72  0.174 versus
10.46  0.163) compared to BHI. Quality-adjusted life expect-
ancy increased by 0.53 years (6.94  0.115 versus 6.39  0.10).
BIAsp was associated with increased total lifetime costs per
patient of CNY 2,386 (247,325  5,897 versus 244,939 
6,922). Thus, BIAsp is associated with an incremental cost-
effectiveness ratio (ICER) of CNY 4315 per quality-adjusted life
year (QALYs) gained. Probabilistic sensitivity analysis shows that
the result is robust. CONCLUSIONS: Long term (life time) pro-
jections of the short-term clinical improvements from the
Chinese IMPROVE study suggest that BIAsp is a cost-effective
treatment compared to BHI, with an ICER below what would be
considered cost-effective in China, using cost-effectiveness
thresholds of 2–3 times GDP per capita, suggested by the WHO.
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OBJECTIVES: Type 2 Diabetes mellitus (T2DM) is a frequent
comorbid condition with obesity. The increasing prevalence of
obesity in the USA, coupled with the rising prevalence of T2DM
and the high up-front cost of bariatric surgery, has necessitated
payers to question the cost-effectiveness of bariatric surgery as a
treatment for T2DM. Our analyses compared cost-effectiveness
of the Roux-En-Y gastric bypass surgery with medical manage-
ment for T2DM patients using clinical outcomes data from a
bariatric surgery practice at the University of Minnesota and
modeling these 2-year observational follow-up data to a lifetime
horizon. METHODS: The CORE Diabetes Model was used to
project lifetime clinical and economic outcomes for T2DM
patients undergoing bariatric surgery. The baseline mean HbA1c
(7.7%), age (50.7), body mass index (48.8 kg/m2), gender (22%
male), race/ethnicity, and risk factors were taken the University
of Minnesota cohort (n = 169). Remaining cohort characteris-
tics, transition probabilities, utilities, direct treatment, and com-
plication costs were obtained from published sources. All costs
and clinical outcomes were discounted at 3% per annum.
RESULTS: Average lifetime total direct costs per patient were
$96,696 (3,349) for Roux-En-Y gastric bypass and $77,169
(2,674) for medical management. Discounted life expectancy
and quality-adjusted life years (QALYs) increased by 0.578
(0.470) years and 0.827 (0.501) QALYs, respectively, for
Roux-En-Y gastric bypass compared with medical management.
The resulting incremental cost-effectiveness ratios (ICERs) for
Roux-En-Y gastric bypass compared with medical management
were $33,795/life-year gained and $23,618/QALY gained.
Probabilistic sensitivity analysis demonstrated a 79.3% likeli-
hood of the cost/QALY being $50,000/QALY for Roux-En-Y
gastric bypass compared with medical management. CONCLU-
SIONS: Cost-effectiveness was driven primarily by superior
HbA1c, lipid reductions, and weight loss. The ICERs obtained in
our analyses provide evidence for the long-term cost-effectiveness
of Roux-En-Y gastric bypass as a treatment for T2DM and is
consistent with current threshold values in the USA for health
technology assessment.
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OBJECTIVES: The aim of the study was to evaluate the cost-
utility of insulin glargine versus NPH and premix in patients with
DM2 with baseline HbA1c above 8% and age below 65 years in
Poland. METHODS: The method adapted was a cost utility
analysis with a 40 year time horizon and public payer perspec-
tive. The model used is a DES model based on the UKPDS 68
equations which has the ability to assess the economic impact
and health consequences outlined as the development of
co-morbidities of a reduction in hypoglycemia, an improvement
in glycaemia or both of these at the same time. A cohort of 1000
patients was generated in the model. Glycaemic control has been
incorporated into the model using results from The Health
Improvement Network (THIN) database. Polish costs were
applied in the model and only direct medical costs were consid-
ered in the analysis. Sensitivity analysis was performed. The
study was conducted according to the Polish HTA guidelines. In
the analysis patients were divided into three groups by age and
baseline HbA1c level. RESULTS: When comparing glargine to
NPH the analyses showed that for patients with age <= 65 and
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baseline HbA1c >= 8% the cost per QALY was estimated at
52,554PLN; for patients with age <= 55 and baseline
HbA1c >= 9% at 50,139 PLN and for patients with age <= 45
and baseline HbA1c >= 10% at 32,689PLN. In the same patient
groups in the analysis for insulin glargine vs pre mix costs per
QALY were estimated at 47,171PLN; 40,055PLN; 23,980PLN
respectively. CONCLUSIONS: The analysis showed that glargine
compared to NPH and premix is a cost effective option for
treatment of type 2 diabetes in Poland in patients with baseline
HbA1c above 8% and age below 65 years. The results of the cost
utility analysis are well below the cost—effectiveness threshold in
Poland (equals to 83,239 PLN/QALY).
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OBJECTIVES: To calculate cost-effectiveness ratios [incremen-
tal cost per quality-adjusted-life-year (QALY) gained] for soma-
tropin (Genotropin®) treatment of adult patients with growth
hormone deﬁciency (GHD) due to non-functioning pituitary
adenoma compared to no growth hormone replacement treat-
ment. METHODS: A Markov-type cost-utility simulation
model was constructed and used in order to simulate, for a male
and female cohort, morbidity and mortality for treated and not
treated individuals over a 20-year time horizon. The calcula-
tions were performed using 2003 prices concerning morbidity-
related health care costs, and up-to-date unit cost for
Genotropin®. Costs are expressed in SEK (I Euro = 9.5 SEK).
All costs and effects are discounted at three percent. The total of
550 treated Swedish patients from the KIMS database (Pﬁzer
International Metabolic Database) was used in the calculations.
RESULTS: The results are presented as incremental cost per
QALY gained including both direct and indirect effects and
costs. The weighted sum of all sub-group incremental cost-
effectiveness ratios (excluding indirect effects of mortality), were
SEK141,650 (€14,911) and SEK206,028 (€21,687) for men and
women, respectively. Including also indirect mortality effects
resulted in lower weighted cost-utility ratios: SEK131,474
(€13,839) and SEK150,766 (€15,870) for men and women,
respectively. Key drivers of the results are improvement in
quality of life, increased survival and treatment cost. CONCLU-
SIONS: The results show that the overall cost per QALY is
moderate if compared to informal thresholds applied in Sweden.
Our simulations suggest that at the SEK500,000 (€52,632)/
QALY-threshold, treatment with Genotropin® has a 100%
probability of being cost-effective for men and at least 90% for
women.
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OBJECTIVES: The goal of the study was to evaluate the cost-
utility of Insulin glargine versus NPH and premix in patients with
type 1 diabetes mellitus with baseline HbA1c above 8%, applied
in a Polish setting. METHODS: The method adapted was a
cost-utility analysis with a 40 year time horizon. The model used
in this evaluation is a Discrete Event Simulation (DES) model
primarily based on the DCCT study which has the ability to
assess the economic impact and health consequences outlined as
the development of co-morbidities of a reduction in hypoglyce-
mia, an improvement in glycaemia or both of these at the same
time. The time increment applied is in yearly increments and the
model was designated to simulate a cohort of 1000 patients.
Hypoglycaemia rates and rate reductions were drawn from peer-
reviewed publications. Glycaemic control has been incorporated
into the model using results from The Health Improvement
Network (THIN) database. Polish costs were applied in the
model and only direct medical costs were considered in the
analysis. The analysis was conducted according to HTA guide-
lines in Poland and included also sensitivity analysis. RESULTS:
When comparing insulin glargine to NPH the analyses showed
that the in patients with baseline HbA1c >= 10%,
HbA1c >= 9%, HbA1c >= 8% the cost per QALY for insulin
glargine vs NPH was estimated at 34,810 PLN; 26,197PLN;
38,110PLN respectively. In the same subgroups analysis for
glargine vs premix in patients with baseline HbA1c >= 10%,
HbA1c >= 9%, HbA1c >= 8% cost per QALY was estimated at
33,000PLN; 29,004PLN; 47,661PLN. CONCLUSIONS: The
analysis showed that glargine compared to NPH and premix is a
cost-effective option for treatment of type 1 diabetes in Poland in
patients with baseline HbA1c above 8%. The outcomes of the
cost-utility analysis are well below the cost-effectiveness thresh-
old in Poland (equals to 83,239PLN/QALY).
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OBJECTIVES: The aim of the study was to evaluate the relative
cost-utility of Insulin glargine versus NPH in people with type 1
diabetes applied in a Polish setting. METHODS: The method
adapted was a cost-utility analysis with a 40 year time horizon.
The model used in this evaluation is a Discrete Event Simulation
(DES) model primarily based on the DCCT study which has the
ability to assess the economic impact and health consequences
outlined as the development of co-morbidities of a reduction in
hypoglycemia, an improvement in glycaemia or both. The time
increment applied is in yearly increments and the model was
designated to simulate a cohort of 1000 patients. Hypoglycemia
rates and rate reductions were drawn from peer-reviewed publi-
cations. Glycaemic control has been incorporated into the model
using results from the THIN database. Polish costs were applied
in the model and only direct medical costs were considered.
Sensitivity analysis was performed. The study was conducted
according to the Guidelines for conducting HTA analysis in
Poland. The perspective of the study is the public payer. Costs
and beneﬁts were discounted at 5%. RESULTS: When compar-
ing insulin glargine to NPH the analyses showed that the cost per
QALY was estimated at 47 369PLN (using base case results for
background hypoglycemia events). The total estimated dis-
counted costs over a lifetime for glargine compared to NPH were
43 854 865PLN and 23 072 257PLN for insulin glargine and
NPH respectively, total estimated discounted QALYs were 8 683
and 8 456 for insulin glargine and NPH respectively. CONCLU-
SIONS: The results showed that glargine compared to NPH
A508 Abstracts
